Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients
|ClinicalTrials.gov Identifier: NCT00204334|
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : January 13, 2010
Correction of anaemia in renal transplant recipients by parenteral application of recombinant erythropoietin and if necessary iron will improve large artery function (endothelial function and elasticity), as assessed by ultrasound techniques and applanation tonometry.
The changes in large artery function will be reflected by changes in serological markers of endothelial function and oxidative stress and by changes in monocyte function and apoptosis.
There are gender differences in the responses of vascular function to correction of anemia.
Besides improvement of large artery function, correction of anemia will also affect parameters of graft function, i.e. glomerular and tubular proteinuria.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Transplantation Anemia||Drug: darbopoeitin||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Anemia Correction on Vascular Function, Endothelial Cell Markers and Monocyte Apoptosis in Renal Transplant Recipients|
|Study Start Date :||June 2005|
|Primary Completion Date :||January 2010|
|Study Completion Date :||January 2010|
- Vessel wall stiffness
- expression of endothelial cell markers
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00204334
|Münster, NRW, Germany, 48149|
|Principal Investigator:||Martin Hausberg, MD||UKM- Medical Department D|